【摘要】 目的探讨11C-蛋氨酸(MET)PET/CT显像对脑胶质瘤的应用价值。方法2例正常对照者、2例脑胶质瘤初诊患者和23例脑胶质瘤术后患者行11C—MET PET/CT显像;25例患者中有17例同时行18F-脱氧葡萄糖(FDG)PET/CT显像。临床随访时间3-17个月。结果4例脑胶质瘤术后无肿瘤残余或复发者11C—MET显像为阴性,其中3例同时行18F—FDG显像也为阴性。2例胶质瘤Ⅱ级初诊者和19例脑胶质瘤术后残余、复发者中,20例11C—MET显像阳性(肿瘤/灰质、肿瘤/白质比值分别为2.02±0.96、3,01±1.79),其中14例同时行18F—FDG显像中12例为阳性。11C—MET显像所见病灶远较18F-FDG显像清晰。14例患者11C-MET、18F—FDG显像的肿瘤/灰质、肿瘤/白质比值分别为2.15±1.16比0.97±0.43(P<0.01)、3.31±2.16比1.90±0.67(P<0.05)。结论11C—MET对脑胶质瘤的显像、定位优于18F—FDG。更多还原

【Abstract】 Objective To study the clinical value of 11C-methionine (MET) PET/CT imaging in brain glioma. Methods 27 cases were studied including 2 glioma, 23 operated glioma and 2 healthy volunteers. 11C-MET PET/CT was performed in all cases but 18F-fluorodeoxyglucose (FDG) PET/CT in only 17 cases. Follow-up period was within 3 - 17 months. Results 11C-MET was negative in 4 cases and 18F-FDG negative in 3 cases in group without remnant or recurrent tumor after operation. In 2 cases of initial glioma and 19 cases with remnant or recurrent tumor group, 11C-MET imaging was positive in 20 cases, tumor/gray matter ratio and tumor/white matter ratio were 2. 02 ±0. 96, 3.01 ± 1. 79 , respectively , among them 14 cases also with F-FDG imaging showed positive in 12 cases. Lesions showed by 11C-MET were far more clear than that of 18F-FDG. Also tumor/gray matter ratio and the tumor/white matter ratio of 11C-MET imaging were significantly higher than 18F-FDG (2. 15 ± 1. 16 vs 0. 97 ±0. 43 ,P < 0. 01; 3. 31 ± 2. 16 vs 1. 90 ± 0. 67 , P < 0. 05). Conclusion 11 C-MET PET/CT is superior to 18 F-FDG PET/CT in the diagnosis and localization of brain glioma.更多还原